产品
编 号：F689279
分子式：C24H30FNO6
分子量：447.5
分子式：C24H30FNO6
分子量：447.5
产品类型
规格
价格
是否有货
结构图
CAS No: 1450642-92-8
产品详情
生物活性：
Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response.
体内研究：
After 8 weeks of diabetes, Cemdomespib (KU-596; 2, 10, or 20 mg/kg ; i.p.; administered for 6 weeks via a once per week) dose-dependently reverses the pre-existing psychosensory deficits. Cemdomespib also dose-dependently prevents the diabetes-induced deficits in motor (MNCV) and sensory (SNCV) nerve conduction velocities.Cemdomespib (20 mg/kg; oral gavage once per week for 4 weeks) significantly reverses the sensory hypoalgesia in WT mice but not the Hsp70 KO mice.Animal Model:Diabetic Swiss Webster mice
Dosage:2, 10, or 20 mg/kg
Administration:Administered after 8 weeks of diabetes via once per week intra-peritoneal injections.
Result:Improved diabetes induced hypoalgesia and sensory neuron bioenergetic deficits in a dose-dependent manner.
Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response.
体内研究：
After 8 weeks of diabetes, Cemdomespib (KU-596; 2, 10, or 20 mg/kg ; i.p.; administered for 6 weeks via a once per week) dose-dependently reverses the pre-existing psychosensory deficits. Cemdomespib also dose-dependently prevents the diabetes-induced deficits in motor (MNCV) and sensory (SNCV) nerve conduction velocities.Cemdomespib (20 mg/kg; oral gavage once per week for 4 weeks) significantly reverses the sensory hypoalgesia in WT mice but not the Hsp70 KO mice.Animal Model:Diabetic Swiss Webster mice
Dosage:2, 10, or 20 mg/kg
Administration:Administered after 8 weeks of diabetes via once per week intra-peritoneal injections.
Result:Improved diabetes induced hypoalgesia and sensory neuron bioenergetic deficits in a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备